HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $22.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 247.55% from the company’s previous close.

YMAB has been the topic of a number of other research reports. Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective on the stock. Wedbush reiterated an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Friday, January 10th. Finally, Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $20.89.

Y-mAbs Therapeutics Price Performance

Shares of YMAB opened at $6.33 on Monday. The company has a market capitalization of $283.51 million, a P/E ratio of -11.72 and a beta of 0.69. Y-mAbs Therapeutics has a one year low of $6.01 and a one year high of $20.90. The business’s 50 day simple moving average is $10.15 and its 200-day simple moving average is $12.09.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The business had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the previous year, the firm posted ($0.18) EPS. On average, sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.66 EPS for the current fiscal year.

Institutional Trading of Y-mAbs Therapeutics

A number of large investors have recently made changes to their positions in YMAB. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Y-mAbs Therapeutics in the third quarter valued at about $44,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Y-mAbs Therapeutics by 66.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after buying an additional 3,416 shares during the period. Intech Investment Management LLC bought a new stake in shares of Y-mAbs Therapeutics during the third quarter worth $133,000. SG Americas Securities LLC acquired a new stake in shares of Y-mAbs Therapeutics during the third quarter worth $178,000. Finally, Empire Financial Management Company LLC acquired a new stake in shares of Y-mAbs Therapeutics during the third quarter worth $210,000. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.